Nutcracker Therapeutics Revenue and Competitors

Location

$74M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Nutcracker Therapeutics's estimated annual revenue is currently $34.1M per year.(i)
  • Nutcracker Therapeutics's estimated revenue per employee is $193,750
  • Nutcracker Therapeutics's total funding is $74M.

Employee Data

  • Nutcracker Therapeutics has 176 Employees.(i)
  • Nutcracker Therapeutics grew their employee count by 3% last year.

Nutcracker Therapeutics's People

NameTitleEmail/Phone
1
Co-Founder & CEOReveal Email/Phone
2
Chief Human Resources OfficerReveal Email/Phone
3
Chief Operating OfficerReveal Email/Phone
4
VP and Head Non-Clinical and Clinical DevelopmentReveal Email/Phone
5
EVP and General CounselReveal Email/Phone
6
Head Facilities, Engineering, EHS, Logistics, Procurement and Real EstateReveal Email/Phone
7
VP AdministrationReveal Email/Phone
8
VP, Partnerships & Intellectual PropertyReveal Email/Phone
9
Director, Analytical DevelopmentReveal Email/Phone
10
Senior Director Supply ChainReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Nutcracker Therapeutics?

Nutcracker Therapeutics is an early stage biotech disrupter founded to develop mRNA-based therapeutic drug products which will be manufactured on our novel ACORN (Automation COntroled RNA) microfluidic based manufacturing system. ACORN is a fully automated, software-controlled microfluidics platform. Our advanced technology-driven approach to therapeutics manufacturing addresses significant challenges associated with production and scale-up of therapeutic products. Automation and microfluidics deliver significantly reduced production cycle times, increased process control, efficiency and reproducibility while greatly reducing manual manipulations, risks of contamination and costly facilities. Through the introduction of breakthrough therapeutic micro factories, Nutcracker is poised to deliver on our mission to significantly improve patient's lives.

keywords:N/A

$74M

Total Funding

176

Number of Employees

$34.1M

Revenue (est)

3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Nutcracker Therapeutics News

2022-03-22 - Nutcracker Therapeutics Raises $167 Million in Series C ...

Nutcracker Therapeutics' RNA manufacturing platform is at the core of the company's therapeutic effort. It combines RNA biochemistry with...

2022-03-22 - Nutcracker snags $167M series C to develop 'push-button ...

Nutcracker Therapeutics wants to create mRNA medicines with the push of a button, a tough nut to crack that is now backed by Arch Venture Partners and...

2022-03-22 - Nutcracker Therapeutics raises $167m to advance mRNA ...

Nutcracker Therapeutics, a biotech developing RNA therapeutics using its proprietary biochip-based manufacturing platform, has raised $167m...

2020-09-25 - Nutcracker Therapeutics Raises $60M in Series B Financing

Nutcracker Therapeutics, Inc., an Emeryville, Calif.-based company developing and producing mRNA therapeutics on its proprietary, microfluidic, biochip-based platform, raised $60m in Series B financing. The round was led by Arch Venture Partners with participation from Bluebird Ventures, a firm ...

2020-09-23 - Nutcracker Therapeutics Announces $60 Million Series B Financing to Advance mRNA Therapeutics Produced on Transformational Biochip-Based ACORN Platform

EMERYVILLE, Calif., Sept. 23, 2020 /PRNewswire/ -- Nutcracker Therapeutics, Inc., a company developing and producing mRNA therapeutics on its proprietary, microfluidic, biochip-based platform, today announced that it has raised $60 million in Series B financing led by ARCH Venture Partners wit ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$31.2M2074%$164.5M
#2
$41.1M2129%$26.1M
#3
$46.5M2332%$396M
#4
$64.9M23622%N/A
#5
$55M23831%N/A